SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

NanoLogix, Inc. (NNLX)

NNLX RSS Feed
Add NNLX Price Alert      Hide Sticky   Hide Intro
Moderator: Sad Pepe, capitalismforever, Emerald Isle
Search This Board: 
Last Post: 4/23/2017 8:34:49 PM - Followers: 132 - Board type: Free - Posts Today: 0


ABOUT NANOLOGIX 

The primary focus of NanoLogix is rapid detection of bacteria and other microorganisms.

Uses for NanoLogix's very-rapid diagnostics include biodefense, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing. Rapid detection of microorganisms is an annual multi-billion dollar market.

NanoLogix has been issued 33 patents in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.


Mission

NanoLogix is a biotechnology company focused on sale of Petri plates packaged in an exclusive licensed Flatpack and the N-Assay rapid detection technology for bacteria, mold, and spores.

NanoLogix technology is used to test for bacteria and other microorganisms and in some cases, dependent upon the technology used, provide for early detection of bacteria and other microorganisms present in infectious and noninfectious human diseases, the environment, industrial and manufacturing settings, veterinary medicine, and research and testing laboratories.


History

NanoLogix began 26 years ago under the name Infectech. From its founding through 2007 the Company had been issued patents that were in some cases practically, and in other cases theoretically, applicable in the areas of applied microbiology, soil microbiology, medical diagnostics, microbial physiology, pharmacology, pharmaco-kinetics, and determination of antibiotic sensitivity.

In 2007, with a management change, the focus of the company changed from Research and Development to exploring how to capitalize on the company's existing intellectual property. It became obvious that the patents of the past possessed little monetary value for the future and that realization resulted in a further change in direction seeking to focus on practicality in research and a focus on a long term future return for the company and its shareholders. The period from 2007 through 2011 resulted in the abandonment of any focus on the production of hydrogen through bacteria degradation of organic waste utilizing what was referred to as a "bioreactor". The reason for the abandonment of the technology was the discovery of a lack of evidence for any economic potential for the technology. A similar discovery led to the practical abandonment of the NanoLogix BNC (BioNanoChannel) technology. While potentially a novel approach to diagnostics, major-lab third-party tests and a subsequent economic analysis demonstrated that under no conditions could the cost of both the antibody coating and specialized glass microchannel disc contained in the apparatus be reduced to a level to enable effective marketing.   Over the following year, NanoLogix went through a transition to production of  FlatPack™ Petri plates and BNP™ diagnostic test kits. Sales of both began in Q3 2012.

NanoLogix's rapid diagnostic technology is the N-Assay modified ELISA diagnostic.


NanoLogix Technology

NanoLogix N-Assay technology provides live-cell rapid detection and identification dramatically faster than Flow Cytometry and traditional Petri culture methods. Additionally, in contrast to other fast methods such as Polymerase Chain Reaction (PCR), NanoLogix technology does not require large investments in equipment or personnel training.

Rapid diagnostics allow researchers in the lab to test for potentially pathogenic agents faster and develop effective countermeasures more rapidly and economically. This quality presents exciting opportunities in the pharmaceutical design process, and furnishes the following as benefits:

Can begin more effective drug treatment when an infectious disease is identified at an early stage. The spread of infectious disease may be reduced by earlier intervention.

In combat theaters and homeland security settings, the presence of specific pathogens can be detected closer to the epicenter of release. Site decontamination teams can identify surface samples closer to real time, potentially aiding the field process.

Industrial production
of food, beverage, drugs, or beauty productscan be paralyzed by microbial contamination.  The ripple effect may include expensive recalls, bad publicity, and government mandated "microbiology holds" that delay the replacement of product.  Rapid diagnostics can help minimize the impact by limiting the spread of spoiled product.


Market

The volume of Petri dishes used for traditional tests is millions per day worldwide.

According to Industrial Microbiology Market Review, worldwide industrial microbiology testing is undergoing tremendous growth. The same growth pattern is anticipated in the medical microbiological diagnostics market.

NanoLogix's potential customers are numerous and varied. They include microbiological laboratories in the industrial, medical, environmental, governmental (federal, state and local) sectors, research and development facilities, and educational institutions.


R&D

NanoLogix's research and development continues on other diagnostic technology with variants in the N-Assay currently being developed for one of the world's largest medical device companies.


Research Article

Development of a Novel Test for Simultaneous Bacterial Identification and Antibiotic Susceptibility
Jonathan Faro,1 Malika Mitchell,2 Yuh-Jue Chen,2 Sarah Kamal,2 Gerald Riddle,1 and Sebastian Faro1

1The Woman’s Hospital of Texas, 7400 Fannin Suite 930, Houston, TX 77054, USA
2The University of Texas Health Science Center at Houston, Medical College, Houston, TX 77054, USA

Received 13 May 2016; Accepted 10 August 2016

Academic Editor: Bryan Larsen

Copyright © 2016 Jonathan Faro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstact

Background. Elucidation of a pathogen’s antimicrobial susceptibility requires subculture after the organism is first isolated. This takes several days, requiring patients to be treated with broad-spectrum antibiotics. This approach contributes to the development of bacterial resistance. Methods. Microtiter wells were coated with a polyclonal antibody targeting the pathogen of interest. Bacterial suspensions were added in the presence/absence of selected antibiotics. After washing, captured bacteria were detected. Findings. Group B streptococcus (GBS), Enterococcus faecalis, and Neisseria gonorrhoeae were each detected at 105 bacteria/mL following a 20-minute incubation period. Susceptibility to select antibiotics was discernable following a 6-hour incubation period (GBS and Enterococcus). Sensitivity was increased to 10−2 bacteria/mL for GBS, 10−1 bacteria/mL for E. faecalis, and 101 bacteria/mL for N. gonorrhoeae following 18–24-hour culture. Conclusion. This novel assay allows for the highly sensitive and specific identification of a pathogen and simultaneous determination of its antimicrobial susceptibility in a reduced time.


Patents

A partial list of Infectech's (now NanoLogix) patents:

http://nanologix.com/downloads/resources_patents.pdf


United States patents that are assigned to NanoLogix:


Production of hydrogen gas and isolation of hydrogen producing microorganisms using replenishing coated substrates - Patent
7,473,552

Method and device for rapid detection of microorganisms by changing the shape of micro-colonies - Patent 7,524,623

Micromethod and device for rapid detection, enumeration and identification of entities - Patent 7,781,159

Method and device for rapid detection of microorganisms by changing the shape of micro-colonies in micro-channels - Patent 8,067,154

Micromethod and device for the rapid detection, enumeration and identification of microorganisms - Patent 8,361,783

Apparatus for making a solid nutrient medium and associated method - Patent 8,420,384

Device for rapid detection and identification of single microorganisms without preliminary growth - Patent 8,663,909


United States patents that are licensed to NanoLogix:

Flat Packaging of Petri Dishes for Prolonged Preservation and Method of Producing the Same - Patent 8,413,900


Rapid enzyme-linked immunosorbent assay for detection and identification of pathogens and determination of antimicrobial susceptibility - Patent
9,034,583

Methods and devices for rapid detection and identification of live microorganisms by aptamers and/or antibodies immobilized on permeable membranes - Patent 9,068,216


Share Structure

Estimated Market Cap: $10,206,995 as of April 24, 2017.

Outstanding Shares: As of April 24, 2017, the company has 145,814,222 shares outstanding. Shares outstanding on December 31, 2014 were 139,531,530 shares.

Authorized Shares: 200,000,000 as of April 24, 2017.

Number of Shareholders of Record: 2,000+/- shareholders as of end of 2015.

Float: 111,329,363 shares as of April 24, 2017.


Press Releases and Company Updates


http://nanologix.com/news/press_releases.html

http://nanologix.com/news/updates.html



Price Quote

http://www.investorshub.com/boards/quotes.asp?ticker=NNLX


NNLX Charts

(1 month daily, 3 month daily, 1 year weekly)




_________________________________________________________________________________________________________________________________________

Contacts

NanoLogix Inc.
843 North Main Street
Hubbard, OH 44425 USA
330-534-0800 (main line)
330-534-0826 (fax)

info@nanologix.com

Pacific Stock Transfer
6725 Via Austi Parkway
Suite 300
Las Vegas, NV 89119
800-785-7782
info@pacificstocktransfer.com
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NNLX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#8230  Sticky Note EVERYONE get your posts back on-topic. The IH Geek [Dave] 11/21/13 03:54:06 PM
#9289   Emerald Isle is still a moderator of this Sad Pepe 04/23/17 01:06:16 PM
#9288   What happened to Emerald Isle? Are you still jshdan 04/23/17 01:01:24 PM
#9287   Hello all, Sad Pepe 04/23/17 12:43:40 PM
#9286   Thank you, capitalismforever. EOM Sad Pepe 04/22/17 07:32:41 PM
#9285   Transfer Agent capitalismforever 04/22/17 06:17:51 PM
#9284   Does anyone know the company's transfer agent and Sad Pepe 04/22/17 10:35:35 AM
#9283   Ok. I get it. You thought I meant Emerald Isle 04/21/17 04:32:55 PM
#9282   I approached them after I became a moderator Emerald Isle 04/21/17 04:18:35 PM
#9281   Seems odd. I didn't think they paid close jshdan 04/21/17 01:44:08 PM
#9280   Thank you, EI. EOM Sad Pepe 04/20/17 01:26:39 PM
#9279   I anticipate within a week. I received an Emerald Isle 04/20/17 12:43:03 PM
#9278   Thank you for the heads up, EI. Any Sad Pepe 04/20/17 12:27:04 PM
#9277   FYI: I've been asked to prepare space for Emerald Isle 04/20/17 09:36:49 AM
#9276   Completely agree. capitalismforever 04/17/17 05:51:00 PM
#9275   When shareholders are denied a right to vote, yman 04/17/17 01:14:55 PM
#9274   If I needed investment advice from you, I'd capitalismforever 04/16/17 10:58:33 PM
#9273   It can, take years, depends on resources available. kphone2004 04/16/17 07:59:57 PM
#9272   I've been in this stock for over 10 hdsmonkey 04/16/17 07:44:47 PM
#9271   Progress doesn't take 10 years. capitalismforever 04/16/17 05:51:52 PM
#9270   Remain positive, progress is being made, I remain kphone2004 04/16/17 05:50:32 PM
#9269   The poison pill does not prevent the company capitalismforever 04/15/17 12:21:39 PM
#9268   I certainly was not asking for your sympathy. Abig 04/15/17 09:41:18 AM
#9267   I remember when the company was pushing the capitalismforever 04/15/17 04:16:12 AM
#9266   Another dog and pony show or maybe vacation. yman 04/12/17 10:21:15 PM
#9265   Here we are in the 2nd quarter and yman 04/12/17 10:02:52 PM
#9264   You know me Leroy I drank that koolaid Abig 04/12/17 04:19:24 PM
#9263   One thing for sure, Abig is not a leroy kelly 04/12/17 10:14:46 AM
#9262   The NanoLogix BNP Test it is a truly Longpicker 04/04/17 10:48:54 PM
#9261   NanoLogix has shipped TB test Kits for use kphone2004 04/04/17 08:32:08 PM
#9260   Emerald you could not be further from the truth. Abig 03/17/17 09:39:17 AM
#9259   http://www.justanswer.com/intellectual-property-law/996uc-own-small-llc-sell-few jshdan 03/17/17 01:37:33 AM
#9258   Abig, It seems to me that you've drunk heavily Emerald Isle 03/16/17 04:27:23 PM
#9257   Oh really. I knew on the web site Abig 03/16/17 04:04:15 PM
#9256   Abig, I believe those have been sold on the Emerald Isle 03/16/17 01:43:01 PM
#9255   " The NanoLogix FlatPack is available through www.nanologix.com Abig 03/16/17 01:32:19 PM
#9254   New Update Emerald Isle 03/16/17 12:48:00 PM
#9253   Undisclosed Major Medical Company Claw2011 03/13/17 10:44:32 AM
#9252   Even though delayed, this is medical and FDA scubagallag 03/09/17 10:46:43 AM
#9251   This statement helps me understand why the price dtgsanjose 03/04/17 04:00:29 PM
#9250   One of these days Alice, to the moon! (Honeymooners) AKAPAK 03/02/17 02:04:12 PM
#9249   New Update --- Mega-sized Client requests additional quotes Emerald Isle 03/02/17 01:44:59 PM
#9248   The more things change the more they stay Abig 02/28/17 04:14:51 PM
#9247   Quite a while with no word on a jshdan 02/28/17 12:47:44 PM
#9246   Matt, I'm a moderator here. I update whatever information Emerald Isle 02/07/17 12:50:06 PM
#9245   Matt stop making sense! Bret said so. So Abig 02/07/17 11:00:32 AM
#9244   EI, Do you realize that website modifications are child's play. matt6314 02/07/17 10:17:19 AM
#9243   Just like all the times before. We're johnny canuck 02/02/17 01:32:35 PM
#9242   Abig, Since I have communicated with Nanologix over time Emerald Isle 02/01/17 11:22:08 AM
#9241   The new website looks great!!! Abig 01/31/17 05:05:46 PM
#9239   New Update Emerald Isle 01/09/17 02:34:11 PM
PostSubject